{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Diabetes+Mellitus+Type+2+%28T2DM%29&page=11",
    "query": {
      "condition": "Diabetes Mellitus Type 2 (T2DM)",
      "page": 11
    },
    "page_size": 10
  },
  "pagination": {
    "page": 11,
    "page_size": 10,
    "total_count": 241,
    "total_pages": 25,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Diabetes+Mellitus+Type+2+%28T2DM%29&page=12&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Diabetes+Mellitus+Type+2+%28T2DM%29&page=10&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-13T21:13:37.074Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT00774553",
      "title": "To Evaluate Safety and Tolerability After Multiple Oral Doses of AZD1656 in Type 2 Diabetes Patients on Top of Metformin",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Type 2 Diabetes"
      ],
      "interventions": [
        {
          "name": "AZD1656",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "AstraZeneca",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "30 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "30 Years to 75 Years"
      },
      "enrollment_count": 70,
      "start_date": "2008-10",
      "completion_date": "2010-01",
      "has_results": false,
      "last_update_posted_date": "2010-01-15",
      "last_synced_at": "2026-10-13T21:13:37.074Z",
      "location_count": 1,
      "location_summary": "San Antonio, Texas",
      "locations": [
        {
          "city": "San Antonio",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00774553"
    },
    {
      "nct_id": "NCT02057172",
      "title": "Glycaemic Control of Weekly LAPS-Exendin Versus Placebo in Subjects of Type 2 Diabetes",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Type 2 Diabetes"
      ],
      "interventions": [
        {
          "name": "HM11260C",
          "type": "DRUG"
        },
        {
          "name": "liraglutide",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Hanmi Pharmaceutical Company Limited",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "74 Years",
        "sex": "ALL",
        "summary": "18 Years to 74 Years"
      },
      "enrollment_count": 254,
      "start_date": "2014-01",
      "completion_date": "2014-12",
      "has_results": false,
      "last_update_posted_date": "2016-08-09",
      "last_synced_at": "2026-10-13T21:13:37.074Z",
      "location_count": 1,
      "location_summary": "CA, California",
      "locations": [
        {
          "city": "CA",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02057172"
    },
    {
      "nct_id": "NCT04203147",
      "title": "Home-based Diabetes-Modified Behavioral Activation Treatment for Low Income Seniors With T2DM",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Type 2 Diabetes"
      ],
      "interventions": [
        {
          "name": "Supportive Therapy (Control)",
          "type": "BEHAVIORAL"
        },
        {
          "name": "Home DM-BAT",
          "type": "BEHAVIORAL"
        }
      ],
      "intervention_types": [
        "BEHAVIORAL"
      ],
      "sponsor": "State University of New York at Buffalo",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "65 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "65 Years and older"
      },
      "enrollment_count": 200,
      "start_date": "2020-01-03",
      "completion_date": "2026-01-01",
      "has_results": true,
      "last_update_posted_date": "2026-02-24",
      "last_synced_at": "2026-10-13T21:13:37.074Z",
      "location_count": 1,
      "location_summary": "Buffalo, New York",
      "locations": [
        {
          "city": "Buffalo",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04203147"
    },
    {
      "nct_id": "NCT01407003",
      "title": "Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) Assessment of LIK066 in Healthy Subjects and in Patients With Type 2 Diabetes Mellitus (T2DM)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Type 2 Diabetes Mellitus (T2DM)"
      ],
      "interventions": [
        {
          "name": "LIK066",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Novartis Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 138,
      "start_date": "2011-06",
      "completion_date": "2013-02",
      "has_results": false,
      "last_update_posted_date": "2020-12-19",
      "last_synced_at": "2026-10-13T21:13:37.074Z",
      "location_count": 1,
      "location_summary": "Miami, Florida",
      "locations": [
        {
          "city": "Miami",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01407003"
    },
    {
      "nct_id": "NCT04283617",
      "title": "Reversibility of Brain Glucose Transport and Metabolism in T2DM: an Intervention Study",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Diabete Type 2"
      ],
      "interventions": [
        {
          "name": "Intensification of insulin regimen/Nutrition",
          "type": "BEHAVIORAL"
        }
      ],
      "intervention_types": [
        "BEHAVIORAL"
      ],
      "sponsor": "Yale University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "60 Years",
        "sex": "ALL",
        "summary": "18 Years to 60 Years"
      },
      "enrollment_count": 0,
      "start_date": "2021-10-12",
      "completion_date": "2024-03",
      "has_results": false,
      "last_update_posted_date": "2024-02-16",
      "last_synced_at": "2026-10-13T21:13:37.074Z",
      "location_count": 1,
      "location_summary": "New Haven, Connecticut",
      "locations": [
        {
          "city": "New Haven",
          "state": "Connecticut"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04283617"
    },
    {
      "nct_id": "NCT01885260",
      "title": "Safety, Tolerability and Efficacy of ISIS-GCGRRx in Type 2 Diabetes",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Type 2 Diabetes Mellitus"
      ],
      "interventions": [
        {
          "name": "ISIS-GCGRRx - Dose Level 1",
          "type": "DRUG"
        },
        {
          "name": "ISIS-GCGRRx - Dose Level 2",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Ionis Pharmaceuticals, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 77,
      "start_date": "2013-07",
      "completion_date": "2014-11",
      "has_results": false,
      "last_update_posted_date": "2016-07-04",
      "last_synced_at": "2026-10-13T21:13:37.074Z",
      "location_count": 18,
      "location_summary": "Birmingham, Alabama • Muscle Shoals, Alabama • Anaheim, California + 15 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Muscle Shoals",
          "state": "Alabama"
        },
        {
          "city": "Anaheim",
          "state": "California"
        },
        {
          "city": "Chino",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01885260"
    },
    {
      "nct_id": "NCT02502253",
      "title": "BDPP Treatment for Mild Cognitive Impairment (MCI) and Prediabetes or Type 2 Diabetes Mellitus (T2DM)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Mild Cognitive Impairment",
        "Alzheimer's Disease"
      ],
      "interventions": [
        {
          "name": "grape seed polyphenolic extract, resveratrol",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Johns Hopkins University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "50 Years",
        "maximum_age": "90 Years",
        "sex": "ALL",
        "summary": "50 Years to 90 Years"
      },
      "enrollment_count": 14,
      "start_date": "2015-06",
      "completion_date": "2022-06-01",
      "has_results": false,
      "last_update_posted_date": "2022-07-22",
      "last_synced_at": "2026-10-13T21:13:37.074Z",
      "location_count": 1,
      "location_summary": "Baltimore, Maryland",
      "locations": [
        {
          "city": "Baltimore",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02502253"
    },
    {
      "nct_id": "NCT02581657",
      "title": "Study to Assess the Safety, Tolerability, PK and PD Response of PE0139 Injection in Adult Subjects With T2DM",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Type 2 Diabetes Mellitus"
      ],
      "interventions": [
        {
          "name": "PE0139 Injection",
          "type": "DRUG"
        },
        {
          "name": "Placebo Injection",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "PhaseBio Pharmaceuticals Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "18 Years to 80 Years"
      },
      "enrollment_count": 37,
      "start_date": "2015-10",
      "completion_date": "2016-11",
      "has_results": false,
      "last_update_posted_date": "2018-04-10",
      "last_synced_at": "2026-10-13T21:13:37.074Z",
      "location_count": 6,
      "location_summary": "Anniston, Alabama • Huntington Park, California • Bradenton, Florida + 3 more",
      "locations": [
        {
          "city": "Anniston",
          "state": "Alabama"
        },
        {
          "city": "Huntington Park",
          "state": "California"
        },
        {
          "city": "Bradenton",
          "state": "Florida"
        },
        {
          "city": "Hialeah",
          "state": "Florida"
        },
        {
          "city": "New Orleans",
          "state": "Louisiana"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02581657"
    },
    {
      "nct_id": "NCT01044537",
      "title": "A Trial To Assess The Safety, Tolerability, Pharmacokinetics, And Pharmacodynamics Of Single Doses Of PF-04937319 In Subjects With Type 2 Diabetes Mellitus",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Type 2 Diabetes Mellitus"
      ],
      "interventions": [
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "PF-04937319",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Pfizer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 50,
      "start_date": "2010-02",
      "completion_date": "2010-05",
      "has_results": true,
      "last_update_posted_date": "2017-03-10",
      "last_synced_at": "2026-10-13T21:13:37.074Z",
      "location_count": 3,
      "location_summary": "Phoenix, Arizona • Cypress, California • Miami, Florida",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Cypress",
          "state": "California"
        },
        {
          "city": "Miami",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01044537"
    },
    {
      "nct_id": "NCT00819884",
      "title": "To Evaluate 24-hr Glucose After OD vs BD AZD1656",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Type II Diabetes"
      ],
      "interventions": [
        {
          "name": "AZD1656",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "AstraZeneca",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "30 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "30 Years to 75 Years"
      },
      "enrollment_count": 36,
      "start_date": "2009-01",
      "completion_date": "2009-05",
      "has_results": false,
      "last_update_posted_date": "2009-05-07",
      "last_synced_at": "2026-10-13T21:13:37.074Z",
      "location_count": 1,
      "location_summary": "San Antonio, Texas",
      "locations": [
        {
          "city": "San Antonio",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00819884"
    }
  ]
}